Primary Central Nervous System Lymphomas.
Autologous stem cell transplant
High-dose methotrexate
Primary central nervous system lymphoma
Thiotepa
Whole-brain radiation therapy
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
entrez:
21
11
2021
pubmed:
22
11
2021
medline:
19
3
2022
Statut:
ppublish
Résumé
Primary central nervous system lymphoma is a rare and aggressive extranodal non-Hodgkin lymphoma restricted to the brain, spinal cord, cerebrospinal fluid, and eyes. Optimization of treatment including high-dose methotrexate-based chemotherapy followed by consolidation therapy in the form of autologous stem cell transplant or whole-brain radiation leads to improved survival. However, several patients do not respond to upfront therapy and the relapse risk is high. Additionally, there is a risk of delayed neurotoxicity, particularly in older patients. Recent molecular insights underlying the pathophysiology of PCNSL have led to the development of clinical trials involving targeted therapies and immunotherapies for salvage.
Identifiants
pubmed: 34801161
pii: S0889-8588(21)00119-2
doi: 10.1016/j.hoc.2021.09.004
pii:
doi:
Substances chimiques
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
147-159Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.